fashion -WSS

fashion

author：leisure time 2025-09-28 19:42:55 - browse：56

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

“These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

leisure time

WSS

UnitedHealth increases loan offers after Change Healthcare outage

The drug industry has found itself all alone in Washington

Intermittent fasting comes with a heart risk? Not so fast

How to bring more disabled researchers into academia

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Argenx readies a blockbuster opportunity with drug for autoimmune disease

hotspot

fashion

Wikipedia

Peter Hotez and the public health issue of online harassment

Change Healthcare cyberattack prompts Medicare loan program

Cancer drug shortages should be causing more outrage

Neuroscience’s long legacy of racism

23andMe had bad news about my health. I wish a person had delivered it

Methadone treatment changes are coming. Do they go far enough?

Moonlake's readout produced a cash windfall. Risks remain

Baby aspirin cuts fat buildup in liver disease patients, in small study

What does generative AI mean for health care? We asked experts

Physicians and social media: If you see something, say something?

leisure time

Future doctors should be trained to promote social change

U.K. researchers warn about biases in medical devices, algorithms

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Novo Nordisk obesity pill bests Wegovy in early trial

5 to watch: Tech startups trying to solve health care's staffing crisis

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

focus

leisure time

leisure time

focus